Global Prophylactic Human Papillomavirus Vaccines – PharmaPoint Drug Forecast and Market Analysis to 2022


“The Report PharmaPoint: Prophylactic Human Papillomavirus Vaccines – Global Drug Forecast and Market Analysis to 2022 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. –”

The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. The global HPV vaccines market is now well established, yet vaccine coverage rates amongst the traditional target population of adolescent girls remain persistently low. Initially HPV vaccines were developed and marketed solely to protect against cervical cancer. In recent years the role of HPV in other cancers has been increasingly recognized which has facilitated a shift towards vaccinating a wider population, most significant has been the inclusion of males in routine vaccine recommendations in some countries. The current HPV vaccines market is dominated by one major player, Mercks Gardasil, with GlaxoSmithKlines (GSKs) HPV vaccine Cervarix providing the only competition. The introduction of Mercks nine-valent vaccine (V503) is set to change the future landscape of the HPV vaccines sector.

View Report At :


Key Questions Answered

– What environmental factors limit the uptake of current HPV vaccines?

– What opportunities exist to overcome these environmental factors?

– What are the main unmet needs of current HPV vaccines?

– What technologies are positioned to address these unmet needs?

– What opportunities will remain for the development of new HPV vaccines?

– What environmental factors will influence the introduction of novel HPV vaccines?

Key Findings

– New nine-valent HPV vaccines are expected to be widely adopted following market approval, stealing market share from existing vaccines. Though a high price represents a potential barrier to market access.

– Significant environmental barriers to HPV vaccination exist, which currently serve to limit vaccine uptake.

– The emphasis of HPV vaccination is shifting away from an initial focus on cervical cancer prevention in females, towards prevention of a range of cancers in both males and females.

– The inclusion of males in routine HPV vaccine recommendations will expand the size of the HPV vaccines market

Download Sample copy of this Report at :


– Overview of the latest advances in prophylactic vaccination.

– Analysis of the future potential for novel and existing HPV vaccines.

– Key topics covered include unmet needs, opportunities, and drivers and barriers specific to prophylactic HPV vaccines.

Reasons to buy

– Understand the dynamics of the prophylactic HPV vaccines market, and the unique barriers to market access.

– Identify opportunities for the development and delivery of HPV vaccines, and to identify emerging players with potentially strong product portfolios.

– Develop business strategies by understanding the trends shaping and driving the future of prophylactic HPV vaccination.

– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

– Gain insight on the challenges associated with delivering prophylactic HPV vaccines and the impact of novel vaccines.

– Track vaccine sales in the global HPV vaccines market from 2012-2022

Table of Contents

1 Table of Contents

1 Table of Contents 7

1.1 List of Tables 13

1.2 List of Figures 16

2 Introduction 18

2.1 Catalyst 18

2.2 Related Reports 19

2.3 Upcoming Related Reports 19

3 Disease Overview 20

3.1 Etiology and Pathophysiology 21

3.1.1 Etiology 21

3.1.2 Pathophysiology 21

3.2 Symptoms 23

4 Vaccination Recommendations and Coverage Rates 25

4.1 Vaccination Recommendations Overview 25

4.2 US 27

4.2.1 Vaccination Recommendations and Policies 27

4.2.2 Vaccination Coverage 27

4.2.3 Clinical Practice 29

4.3 France 30

4.3.1 Vaccination Recommendations and Policies 30

4.3.2 Vaccination Coverage 31

4.3.3 Clinical Practice 32

4.4 Germany 33

4.4.1 Vaccination Recommendations and Policies 33

4.4.2 Vaccination Coverage 34

4.4.3 Clinical Practice 35

4.5 Italy 36

4.5.1 Vaccination Recommendations and Policies 36

4.5.2 Vaccination Coverage 37

4.5.3 Clinical Practice 39

4.6 Spain 40

4.6.1 Vaccination Recommendations and Policies 40

4.6.2 Vaccination Coverage 41

4.6.3 Clinical Practice 43

4.7 UK 43

4.7.1 Vaccination Recommendations and Policies 43

4.7.2 Vaccination Coverage 44

4.7.3 Clinical Practice 45

4.8 Japan 46

4.8.1 Vaccination Recommendations and Policies 46

4.8.2 Vaccination Coverage 47

4.8.3 Clinical Practice 48

4.9 Australia 49

4.9.1 Vaccination Recommendations and Policies 49

4.9.2 Vaccination Coverage 49

4.9.3 Clinical Practice 51

About us is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.


Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074